FRANCE – Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), has invetsted in AMF-regulated investment company AdBio Partners’ second fund – AFB Fund II.
Adbio Partners Chairman and managing partner Ellen Hurridge said, “We are delighted to welcome Inserm Transfer as an investor in our second fund. It is a prestigious partner within the French and European life sciences industry.
We share the same vision: Entrepreneurship in French Academic Research in Health Fostering and helping to develop an ecosystem that sometimes has a silo mindset, but is also rich in innovation and talented individuals. This is the goal we will pursue together.”
This collaboration will help the most innovative life science startups get off the ground and find funding, as well as strengthen entrepreneurial skills among scientists with academic research backgrounds, such as those at Inserm.
AdBio Partners’ portfolio already includes Alderaan Biotechnology, DiogenX, Tridek-One, and Thabor Therapeutics, all of which have Inserm IP.
This is a clear demonstration of the work already done by both the partners in recent years. AdBio partners’ distinct strategy combines early-stage investments in promising ventures with strong entrepreneurial support to drive company growth.
Since AdBio Partners was founded in 2016, it has made 17 European investments in France, Belgium, Spain, and Ireland.
Inserm Transfert has become the latest international limited partner to invest in AdBio Partners’ second fund. The initial closing, which was announced in September 2021, totaled €86 million (US$102 million).
The European Investment Fund (EIF), the French Seed Fund 2 (FNA 2), managed by Bpifrance on behalf of the French State as part of the future investments program, Boehringer Ingelheim Venture Fund, Pierre Fabre, various family offices, and AdBio partners’ management are among the other investors.
“It’s critical that we keep developing early-stage financing for new companies in France and Europe,” explained Matthieu Coutet, managing partner at AdBio partners.
AdBio partners has assembled a team of experts to meet this challenge and to launch startups in direct collaboration with the scientists and academic researchers at the heart of the innovations; Inserm is a major French player in this sector.
Since 2010, Inserm Transfert has assisted Inserm startups in raising over €1.66 billion (US$1.78 billion). Every year, a dozen startups are founded on Inserm-researched innovations.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
